PROCEPT BioRobotics Corporation Selling, General and Administrative Expense
PROCEPT BioRobotics Corporation (PRCT) reported Selling, General and Administrative Expense of $69.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- PROCEPT BioRobotics Corporation selling, general and administrative expense for the quarter ending 2026-06-30 was $69.67M, a 23.74% increase year-over-year.
- PROCEPT BioRobotics Corporation selling, general and administrative expense for the quarter ending 2026-03-31 was $65.09M, a 17.92% increase year-over-year.
- PROCEPT BioRobotics Corporation selling, general and administrative expense for the quarter ending 2025-12-31 was $58.30M, a 20.66% increase year-over-year.
- PROCEPT BioRobotics Corporation selling, general and administrative expense for the quarter ending 2025-09-30 was $59.01M, a 38.23% increase year-over-year.
- PROCEPT BioRobotics Corporation selling, general and administrative expense for fiscal 2025 was $228.81M, a 33.48% increase from fiscal 2024.
- PROCEPT BioRobotics Corporation selling, general and administrative expense for fiscal 2024 was $171.41M, a 30.08% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation selling, general and administrative expense for fiscal 2023 was $131.77M, a 48.35% increase from fiscal 2022.
- PROCEPT BioRobotics Corporation selling, general and administrative expense for fiscal 2022 was $88.83M, a 74.05% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $69.67M 10-Q · filed 2026-08-05 | $134.76M 10-Q · filed 2026-08-05 | $193.05M derived: sum of 3 quarters · filed 2026-08-05 | $252.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $65.09M 10-Q · filed 2026-04-30 | $123.39M derived: sum of 2 quarters · filed 2026-04-30 | $182.40M derived: sum of 3 quarters · filed 2026-04-30 | $238.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $58.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $117.31M derived: sum of 2 quarters · filed 2026-02-26 | $173.61M derived: sum of 3 quarters · filed 2026-08-05 | $228.81M 10-K · filed 2026-02-26 |
| 2025-09-30 | $59.01M 10-Q · filed 2025-11-05 | $115.31M derived: sum of 2 quarters · filed 2026-08-05 | $170.51M 10-Q · filed 2025-11-05 | $218.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $56.30M 10-Q · filed 2026-08-05 | $111.50M 10-Q · filed 2026-08-05 | $159.82M derived: sum of 3 quarters · filed 2026-08-05 | $202.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $55.20M 10-Q · filed 2026-04-30 | $103.51M derived: sum of 2 quarters · filed 2026-04-30 | $146.20M derived: sum of 3 quarters · filed 2026-04-30 | $187.01M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $48.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $91.01M derived: sum of 2 quarters · filed 2026-02-26 | $131.82M derived: sum of 3 quarters · filed 2026-02-26 | $171.41M 10-K · filed 2026-02-26 |
| 2024-09-30 | $42.69M 10-Q · filed 2025-11-05 | $83.50M derived: sum of 2 quarters · filed 2025-11-05 | $123.10M 10-Q · filed 2025-11-05 | $159.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $40.81M 10-Q · filed 2025-08-07 | $80.41M 10-Q · filed 2025-08-07 | $116.72M derived: sum of 3 quarters · filed 2026-02-26 | $149.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $39.60M 10-Q · filed 2025-05-02 | $75.92M derived: sum of 2 quarters · filed 2026-02-26 | $108.80M derived: sum of 3 quarters · filed 2026-02-26 | $141.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $36.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $69.20M derived: sum of 2 quarters · filed 2026-02-26 | $101.64M derived: sum of 3 quarters · filed 2026-02-26 | $131.77M 10-K · filed 2026-02-26 |
| 2023-09-30 | $32.88M 10-Q · filed 2024-10-28 | $65.32M derived: sum of 2 quarters · filed 2024-10-28 | $95.46M 10-Q · filed 2024-10-28 | $121.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $32.44M 10-Q · filed 2024-08-02 | $62.57M 10-Q · filed 2024-08-02 | $88.61M derived: sum of 3 quarters · filed 2025-02-27 | $113.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $30.13M 10-Q · filed 2024-05-02 | $56.16M derived: sum of 2 quarters · filed 2025-02-27 | $80.92M derived: sum of 3 quarters · filed 2025-02-27 | $100.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $26.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $50.79M derived: sum of 2 quarters · filed 2025-02-27 | $70.44M derived: sum of 3 quarters · filed 2025-02-27 | $88.83M 10-K · filed 2025-02-27 |
| 2022-09-30 | $24.75M 10-Q · filed 2023-11-02 | $44.41M derived: sum of 2 quarters · filed 2023-11-02 | $62.79M 10-Q · filed 2023-11-02 | $79.06M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $19.66M 10-Q · filed 2023-07-28 | $38.04M 10-Q · filed 2023-07-28 | $54.31M derived: sum of 3 quarters · filed 2024-02-28 | $66.43M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $18.39M 10-Q · filed 2023-05-04 | $34.66M derived: sum of 2 quarters · filed 2024-02-28 | $46.77M derived: sum of 3 quarters · filed 2024-02-28 | $59.07M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $16.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $28.39M derived: sum of 2 quarters · filed 2024-02-28 | $40.69M derived: sum of 3 quarters · filed 2024-02-28 | $51.04M 10-K · filed 2024-02-28 |
| 2021-09-30 | $12.12M 10-Q · filed 2022-11-04 | $24.42M derived: sum of 2 quarters · filed 2022-11-04 | $34.77M 10-Q · filed 2022-11-04 | $43.90M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $12.30M 10-Q · filed 2022-08-05 | $22.65M 10-Q · filed 2022-08-05 | $31.78M derived: sum of 3 quarters · filed 2022-08-05 | $38.84M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $10.35M 10-Q · filed 2022-05-06 | $19.48M derived: sum of 2 quarters · filed 2022-05-06 | $26.54M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $16.19M derived: sum of 2 quarters · filed 2022-03-22 | $30.27M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $7.05M 10-Q · filed 2021-11-05 | $21.14M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |